DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the VENUS REMEDIES LIMITED (VENUSREM) share price today?

VENUS REMEDIES LIMITED (VENUSREM) is trading at ₹1,770 on the NSE, down 1.03% on the day. Source: DocStoX.

What is the PE ratio of VENUS REMEDIES LIMITED?

VENUS REMEDIES LIMITED has a price-to-earnings (PE) ratio of 23.0 in the Healthcare sector.

What is the market capitalisation of VENUS REMEDIES LIMITED?

VENUS REMEDIES LIMITED has a market capitalisation of approximately ₹2,386 crore.

VENUS REMEDIES LIMITED

VENUSREM·NSE·Healthcare

₹1,770.00▼ -18.50 (-1.03%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

Day₹1705.10

₹1820.00

52W₹424

₹204483%

Open

₹1755.00

High

₹1820.00

Low

₹1705.10

Prev Close

₹1788.50

Volume

30.9K

VWAP

₹1768.14

Snapshot

Key fundamentals

Market Cap

₹2,386 Cr

P/E Ratio

23.02Fair

P/B Ratio

3.53

EPS

₹76.90

Book Value

₹497.00

ROE

16.80%Strong

ROCE

22.00%Efficient

Dividend Yield

0.59%

Debt / Equity

0.02Low

Face Value

₹10.00

52W High

₹2044.30

52W Low

₹424.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹688

▼ 61.2%downside

Trading at ₹1,770 — 61% above our estimate

BearFair valueBull

₹584₹688₹927

/100

Business quality — Solid

Growth 73Profitability 61Efficiency 35Valuation 83

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 3/9)

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 22%)
Profit growing 56% a year

Risks

Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

17% ROE fading to 12% over ~10 yrs, on ₹497 book

₹621

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹927

Analyst target

No analyst coverage

—

Blended fair value₹688

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 22%)
Profit growing 56% a year

Bear case

Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

23.0Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

16.8%Strong

Above 15% is considered healthy for Indian equities

ROCE

22.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.02Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹2,386 Cr

P/B

3.53

EPS

₹76.90

Div Yield

0.59%

What changed

Recent changes

Foreign investors+0.5% stake last quarter
Domestic institutions+0.2% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 23.0×

Growth

Steady

+12% rev CAGR

Profitability

Healthy

16.8% ROE

Financial health

Rock solid

D/E 0.02

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹546.96L Cr

Trades1,824

VWAP₹1768.14

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+11.7%

+7.2%

10Y

+6.6%

Profit

+56.3%

+10.7%

10Y

+48.3%

EPS

+57.0%

+9.0%

10Y

+48.4%

Profile

Pros

Company is almost debt free.
Company has delivered good profit growth of 21.8% CAGR over last 5 years

Watch-outs

Cons

Stock is trading at 3.46 times its book value
The company has delivered a poor sales growth of 7.18% over past five years.
Company has a low return on equity of 10.5% over last 3 years.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors bought 0.54 pts; domestic institutions added 0.17 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

42%

Promoter

Promoters

41.8%0.00

Public

44.4%-0.77

FII / FPI

2.8%+0.54

DII

1.2%+0.17

Others

9.8%

Total shareholders

18,403-203 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter41.76%

FII2.80%

DII1.20%

Public44.39%

Others9.85%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1989, Venus Remedies Ltd is a research based pharmaceutical company and an injectable manufacturer[1]